featured
2022 Top Story in Metastatic Breast Cancer: Antibody–Drug Conjugates for Metastatic Breast Cancer Treatment
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387(1):9–20.
- Diéras V, Deluche E, Lusque A, et al. Abstract PD8-02: Trastuzumab Deruxtecan (T-DXd) for Advanced Breast Cancer (ABC) Patients, Regardless of HER2 Status: A Phase II Study With Biomarkers Analysis (DAISY). Cancer Research. 2022 Feb 15. doi: 10.1158/1538-7445.sabcs21-pd8-02. Online ahead of print.
- Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021;384(16):1529–1541.
- Rugo HS, Bardia A, Tolaney SM, et al. TROPiCS-02: A Phase III Study Investigating Sacituzumab Govitecan in the Treatment of HR+/HER2– Metastatic Breast Cancer. Future Oncol. 2020;16(12):705–715.
- Schmid P, Cortés J, Marmé F, et al. 214MO Sacituzumab Govitecan (SG) Efficacy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2–) Metastatic Breast Cancer (MBC) by HER2 Immunohistochemistry (IHC) Status in the Phase III TROPiCS-02 Study. Ann Oncol. 2022;33(supply 7):S635–S636.
- Hurvitz SA, Bardia A, Punie K, et al. 168P Sacituzumab Govitecan (SG) Efficacy in Patients With Metastatic Triple-Negative Breast Cancer (mTNBC) by HER2 Immunohistochemistry (IHC) Status: Findings From the Phase 3 ASCENT Study. Ann Oncol. 2022;33(suppl 3):S200–S201.
Disclosure statements are available on the authors' profiles: